Curasight aims to initiate clinical development of uTREAT in mid-2025. We think the data could constitute a major inflection point and that it would have a pretty good chance of eliciting tumour responses. However, Curasight still needs to secure financing for the trial. Prostate uTRACE is recruiting, albeit on the slow side. We update our launch assumptions for uTRACE and uTREAT to 2028 (2027), and our new equity valuation range is DKK 19-51 per share (45-63).

Länk till analysen